Press Releases

ECI’s Product & Packaging Testing Laboratory Achieves ISO/IEC 17025 Accreditation

ECI announced today that its Product & Packaging Testing Laboratory, located in the Coyol Free Zone in Costa Rica, has achieved ISO/IEC 17025:2017 accreditation from A2LA for technical competence in mechanical testing.

Sanofi’s MenQuadfi Wins EU Approval for Infants from Six Weeks Against Meningococcal Disease

Sanofi’s MenQuadfi has received European Commission approval for use in infants from six weeks of age against invasive meningococcal disease caused by serogroups A, C, W and Y. The expanded indication is supported by the MET58 pivotal study and clinical data involving more than 6,000 infants across 11 countries. The approval provides EU healthcare professionals with another option for early protection against a rapidly progressing and potentially fatal infection.

CellCarta Adds Tempus to CDx Commercialization Lab Network

CellCarta today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM).

Proscia Receives New FDA 510(k) Clearance for Concentriq AP-Dx with Predetermined Change Control Plan

Regulatory milestone advances Proscia’s open approach to digital pathology

Verista Announces Appointment of Michael Laferrera as Chief Executive Officer

Verista names seasoned healthcare and pharma services leader as CEO to drive strategic growth, innovation, and operational excellence.

ELRIG Appoints Drs Hitesh Sanganee and Marcus Schindler to Scientific Advisory Board

Leadership expansion reinforces ELRIG's commitment to delivering impactful drug discovery initiatives and driving community-wide collaboration

Novo Nordisk Challenges Lilly’s GLP-1 Advertising Campaigns, Claiming Consumers Are Misled by Outdated Comparisons

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that Lilly’s GLP-1 advertising campaigns use outdated comparisons and mislead consumers about obesity and diabetes treatments. The dispute focuses on advertisements comparing Zepbound® and Mounjaro® with lower doses of Wegovy® and Ozempic®. Novo Nordisk is seeking removal of the campaigns and corrective advertising to ensure patients receive updated scientific information. The case highlights increasing competition between leading pharmaceutical companies in the fast-growing GLP-1 therapy market.

Lilly to Acquire AtaiBeckley to Advance Innovative Biotech Therapies for Treatment-Resistant Depression

Eli Lilly and Company has announced a definitive agreement to acquire clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion, including milestone-based payments. The acquisition significantly expands Lilly's neuroscience pipeline with innovative rapid-acting neuroplastogen therapies for treatment-resistant depression and other serious mental health disorders. The transaction highlights growing pharmaceutical investment in next-generation psychiatric medicines designed to deliver durable symptom relief through novel mechanisms of action.

Trajan Expands US Availability of Harpera™ Microbiopsy Punch for Clinical Skin Sampling

Trajan Scientific and Medical (Trajan), a global developer and manufacturer of analytical, life sciences, and medical technologies, has announced that its Harpera™ Microbiopsy Punch is now FDA-registered for marketing in the US. Previously available in the country for investigational use only, the suture-free device can now be used by healthcare professionals across a broader range of clinical skin sampling applications, alongside clinical research and wellness programs. The registration responds to growing demand from healthcare and research organizations for patient-friendly sampling approaches, offering a minimally invasive alternative to traditional skin biopsy that reduces collection burden while preserving sample quality for modern molecular techniques. Healthcare professionals in the US now gain expanded access to a tool that supports dermatology, biomarker research, and precision medicine, with applications spanning molecular analysis, translational research, and longitudinal skin sampling.

Creative Diagnostics Launches Hantavirus Research Reagents and Products to Accelerate Global Diagnostic and Vaccine Research

Creative Diagnostics announces Hantavirus Research Reagents and Products to support hantavirus research and diagnostic assay development.

Novogene Europe Launches Untargeted Metabolomics Service at Cambridge Omics Centre

• Strengthens multiomics portfolio offering metabolite-level insight to connect molecular data with biological function across broader life science studies • New workflow built around Thermo Scientific Vanquish UHPLC coupled with Orbitrap Exploris 120 high-resolution accurate-mass mass spectrometry

Sanofi Wins FDA Approval for First On-Body Injector Cancer Treatment, Making Multiple Myeloma Care Simpler

The FDA has approved Sanofi's Sarclisa Escena, making it the first anticancer therapy that can be administered through a wearable on-body injector. Clinical studies showed the new subcutaneous treatment delivers effectiveness comparable to intravenous therapy while reducing administration time and infusion-related reactions. The approval is expected to improve both patient convenience and healthcare workflow in the treatment of multiple myeloma.

Novartis to Acquire Myricx Bio in USD 1.5 Billion Deal, Strengthening Next-Generation ADC Cancer Pipeline

Novartis has agreed to acquire UK-based biotech company Myricx Bio in a deal worth up to USD 1.5 billion to strengthen its oncology pipeline. The acquisition brings Myricx's next-generation NMTi antibody-drug conjugate (ADC) platform, designed to overcome resistance to existing cancer therapies. It also adds two lead ADC candidates targeting B7-H3 and HER2, expanding Novartis' portfolio for treating solid tumors. The transaction is expected to close in the second half of 2026, subject to regulatory approvals.

VisualDx Partners with Sun River Health to Expand Access to Clinical Decision Support for Underserved Patients

Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Engineering, Cybersecurity and AI

ECI has announced the appointment of Taranjit S. Samra, DRSc, MSEE, RAC, as Head of Medical Device Software Engineering, Cybersecurity and AI.

Siddharth Mittal Appointed as Managing Director & CEO of Syngene International

eClinical Solutions Advances Risk-Based Quality Management Solutions, Helping Sponsors Meet ICH E6(R3) Regulatory Guidelines

Enhancements further break down silos and reduce fragmentation through integrated risk and quality management within one clinical data intelligence platform

Revecore Launches ReClaim(TM), an AI-Native Platform Built for the Complexity Modern Hospitals Face

Eli Lilly Launches National Sleep Apnea Awareness Campaign with Shaquille O'Neal and Zepbound

Eli Lilly has launched a nationwide awareness campaign featuring basketball legend Shaquille O'Neal to highlight the risks of moderate-to-severe obstructive sleep apnea (OSA). After learning that years of fatigue, loud snoring, and poor sleep were symptoms of OSA, O'Neal began treatment with Zepbound® (tirzepatide). The campaign encourages people experiencing sleep apnea symptoms to seek medical advice and explore treatment options. Zepbound is the first FDA-approved prescription medicine for adults with obesity and moderate-to-severe OSA, helping improve sleep quality and reduce breathing interruptions during sleep.

Bio-Gate: Update on the HIPrevision clinical trial for HyProtect™-coated hip revision implants

Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative healthcare technologies, provides an update on the current status of the clinical development of the HyProtect™ coating for orthopedic implants: Following the completion of the pilot phase, the comprehensive main clinical trial has now commenced. The project – conducted in collaboration with a project partner and initially announced in December 2024 – is on track to reach the next milestone toward CE approval of HyProtect™-coated revision implants.